{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:24Z","timestamp":1787002644167,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent studies have shown that radiation-induced pelvic toxicity often requires urological consultation. However, the 10-year incidence of genitourinary toxicity following intensity-modulated radiotherapy (IMRT) amongst patients with localised prostate cancer remains unclear. Hence, we conducted a systematic review and meta-analysis to determine the incidence of late genitourinary toxicity relying on Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE) grade as well as the incidence of specific genitourinary toxicity. Secondary objectives involved quantifing the number of studies reporting 120-month follow-up endpoints, time to event analysis, predictive factors or economic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Articles published from January 2008 to December 2021 describing prospective studies were systematically searched in MEDLINE, EMBASE and Cochrane (PROSPERO protocol CRD42019133320). Quality assessment was performed by use of the Cochrane Risk of Bias 2 Tool for RCTs and the Newcastle Ottowa Scale for non-RCTs. Meta-analysis was performed on the 60-month incidence of RTOG and CTCAE Grade \u22652 genitourinary toxicity, haematuria, urinary retention and urinary incontinence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We screened 4721 studies and six studies met our inclusion criteria. All included studies involved normofractionation, three included a hypofractionation comparator arm and none involved nodal irradiation. The pooled 60-month cumulative incidence of RTOG and CTCAE Grade \u22652 genitourinary toxicity were 17% (95% CI: 5\u201320%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009678) and 33% (95% CI: 27\u201338%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009153), respectively. The pooled 60-month cumulative incidence of Haematuria was 5% (95% CI: \u22124\u201314%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200948), Urinary incontinence 12% (95% CI: 6\u201318%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009194), Urinary retention 24% (95% CI: 9\u201340%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910). One study reported time to event analyses, one reported predictive factors, no studies reported economic analysis or 120-month toxicity. There was considerable heterogeneity amongst the studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There are few high-quality studies reporting 60-month toxicity rates after IMRT. Conservative estimates of 60-month toxicity rates are high and there is need for longer follow-up and consistent toxicity reporting standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-022-00520-x","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T12:03:30Z","timestamp":1646741010000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-1204","authenticated-orcid":false,"given":"Rowan","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Buckby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman A.","family":"Kahokehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"520_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bju.14145","volume":"121","author":"JL Ma","year":"2018","unstructured":"Ma JL, Hennessey DB, Newell BP, Bolton DM, Lawrentschuk N. Radiotherapy-related complications presenting to a urology department: a more common problem than previously thought? BJU Int. 2018;121:28\u201332.","journal-title":"BJU Int"},{"key":"520_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bju.14251","volume":"121","author":"A Kneebone","year":"2018","unstructured":"Kneebone A, Gysen KV. Is radiotherapy the work of the devil? BJU Int. 2018;121:6\u20137.","journal-title":"BJU Int"},{"issue":"3 SUPPL. 1","key":"520_CR3","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.ijrobp.2010.07.211","volume":"78","author":"JE Bekelman","year":"2010","unstructured":"Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, et al. Comparative effectiveness of intensity modulated (IMRT) versus 3D conformal (CRT) radiotherapy for non-metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78 3 SUPPL. 1:S77.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"520_CR4","doi-asserted-by":"crossref","unstructured":"Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, et al. Intensitymodulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. Jama. 2012;307:1611\u201320.","DOI":"10.1001\/jama.2012.460"},{"key":"520_CR5","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1016\/j.ijrobp.2013.06.459","volume":"87","author":"A Raldow","year":"2013","unstructured":"Raldow A, Presley CJ, Yu JB, Cramer LD, Soulos PR, Long JB, et al. The dissemination of new technologies and temporal trends in curative therapy for prostate cancer patients with low likelihood of clinical benefit. Int J Radiat Oncol Biol Phys. 2013;87:S177\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"520_CR6","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/j.ijrobp.2011.02.006","volume":"81","author":"JE Bekelman","year":"2011","unstructured":"Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:e325\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"520_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta14470","volume":"14","author":"S Hummel","year":"2010","unstructured":"Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1\u2013108.","journal-title":"Health Technol Assess"},{"key":"520_CR8","doi-asserted-by":"publisher","first-page":"e0154499","DOI":"10.1371\/journal.pone.0154499","volume":"11","author":"T Yu","year":"2016","unstructured":"Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS ONE. 2016;11:e0154499.","journal-title":"PLoS ONE"},{"key":"520_CR9","first-page":"6373","volume":"19","author":"N Ohri","year":"2012","unstructured":"Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol. 2012;19:6373\u201380.","journal-title":"Can J Urol"},{"key":"520_CR10","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325\u201332.","journal-title":"J Clin Oncol"},{"key":"520_CR11","doi-asserted-by":"publisher","first-page":"17383","DOI":"10.18632\/oncotarget.14798","volume":"8","author":"R Di Franco","year":"2017","unstructured":"Di Franco R, Borzillo V, Ravo V, Ametrano G, Falivene S, Cammarota F, et al. Rectal\/urinary toxicity after hypofractionated vs conventional radiotherapy in low\/intermediate risk localized prostate cancer: systematic review and meta analysis. Oncotarget. 2017;8:17383\u201395.","journal-title":"Oncotarget."},{"key":"520_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.acuro.2014.12.005","volume":"39","author":"LM Sanchez-Gomez","year":"2015","unstructured":"Sanchez-Gomez LM, Polo-deSantos M, Rodriguez-Melcon JI, Angulo JC, Luengo-Matos S. Hypofractionated radiation therapy versus conventional radiation therapy in prostate cancer: A systematic review of its safety and efficacy. Actas Urol Esp. 2015;39:367\u201374.","journal-title":"Actas Urol Esp"},{"key":"520_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","volume":"68","author":"BF Koontz","year":"2015","unstructured":"Koontz BF, Bossi A, Cozzarini C, Wiegel T, D\u2019Amico A. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68:683\u201391.","journal-title":"Eur Urol"},{"key":"520_CR14","first-page":"3563","volume":"21","author":"R Di Franco","year":"2017","unstructured":"Di Franco R, Borzillo V, Ravo V, Ametrano G, Cammarota F, Rossetti S, et al. Rectal\/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis. Eur Rev Med Pharmacol Sci. 2017;21:3563\u201375.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"520_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CE.S41178","volume":"8","author":"TE Botrel","year":"2013","unstructured":"Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis. Core Evid. 2013;8:1\u201313.","journal-title":"Core Evid"},{"key":"520_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ctrv.2013.01.008","volume":"39","author":"NG Zaorsky","year":"2013","unstructured":"Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev. 2013;39:728\u201336.","journal-title":"Cancer Treat Rev"},{"key":"520_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.radonc.2008.01.012","volume":"86","author":"SM Bentzen","year":"2008","unstructured":"Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol. 2008;86:142\u20137.","journal-title":"Radiother Oncol"},{"key":"520_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.7326\/0003-4819-148-6-200803180-00209","volume":"148","author":"TJ Wilt","year":"2008","unstructured":"Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435\u201348.","journal-title":"Ann Intern Med"},{"key":"520_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7330","volume":"7","author":"S Hummel","year":"2003","unstructured":"Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess. 2003;7:1\u2013157.","journal-title":"Health Technol Assess"},{"key":"520_CR20","unstructured":"David ROM, Lee J, Watson D, Kahokehr A. A systematic review of the incidence of late genitourinary complications after prostate radiation therapy.: PROSPERO 2019 CRD42019133320. 2019. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42019133320."},{"key":"520_CR21","doi-asserted-by":"crossref","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361.","DOI":"10.1002\/jrsm.1411"},{"key":"520_CR22","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.3390\/cancers3033419","volume":"3","author":"J Sia","year":"2011","unstructured":"Sia J, Joon DL, Viotto A, Mantle C, Quong G, Rolfo A, et al. Toxicity and long-term outcomes of dose-escalated intensity modulated radiation therapy to 74Gy for localised prostate cancer in a single Australian centre. Cancers. 2011;3:3419\u201331.","journal-title":"Cancers."},{"key":"520_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ijrobp.2008.04.063","volume":"73","author":"A Al-Mamgani","year":"2009","unstructured":"Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"520_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17:464\u201374.","journal-title":"Lancet Oncol"},{"key":"520_CR25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","volume":"102","author":"R de Crevoisier","year":"2018","unstructured":"de Crevoisier R, Bayar MA, Pommier P, Muracciole X, Pene F, Dudouet P, et al. Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2018;102:1420\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"520_CR26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.01.016","volume":"100","author":"JM Wilson","year":"2018","unstructured":"Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, et al. The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol, Phys. 2018;100:1179\u201389.","journal-title":"Int J Radiat Oncol Biol, Phys"},{"key":"520_CR27","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884\u201390.","journal-title":"J Clin Oncol"},{"key":"520_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.radonc.2009.03.013","volume":"92","author":"V Fonteyne","year":"2009","unstructured":"Fonteyne V, Villeirs G, Lumen N, De Meerleer G. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol. 2009;92:42\u20137.","journal-title":"Radiother Oncol"},{"key":"520_CR29","doi-asserted-by":"publisher","first-page":"346812","DOI":"10.1155\/2015\/346812","volume":"2015","author":"C Browne","year":"2015","unstructured":"Browne C, Davis NF, Mac Craith E, Lennon GM, Mulvin DW, Quinlan DM, et al. A narrative review on the pathophysiology and management for radiation cystitis. Adv Urol. 2015;2015:346812.","journal-title":"Adv Urol"},{"key":"520_CR30","doi-asserted-by":"crossref","unstructured":"Denton AS, Clarke NW, Maher EJ. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev. 2002;2002:CD001773.","DOI":"10.1002\/14651858.CD003455"},{"key":"520_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0022-5347(17)37924-7","volume":"146","author":"FJ Greskovich","year":"1991","unstructured":"Greskovich FJ, Zagars GK, Sherman NE, Johnson DE. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol. 1991;146:798\u2013802.","journal-title":"J Urol"},{"key":"520_CR32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/bju.12291","volume":"112","author":"H Payne","year":"2013","unstructured":"Payne H, Adamson A, Bahl A, Borwell J, Dodds D, Heath C, et al. Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int. 2013;112:885\u201397.","journal-title":"BJU Int"},{"key":"520_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41391-017-0028-3","volume":"21","author":"MA Awad","year":"2018","unstructured":"Awad MA, Gaither TW, Osterberg EC, Murphy GP, Baradaran N, Breyer BN. Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21:168\u201374.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"520_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1464-410X.2012.11597.x","volume":"111","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111:437\u201350.","journal-title":"BJU Int"},{"key":"520_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1781-z","volume":"16","author":"V Becerra","year":"2016","unstructured":"Becerra V, \u00c1vila M, Jimenez J, Cortes-Sanabria L, Pardo Y, Garin O, et al. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review. BMC Health Serv Res. 2016;16:541.","journal-title":"BMC Health Serv Res"},{"key":"520_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","volume":"99","author":"NR Datta","year":"2017","unstructured":"Datta NR, Stutz E, Rogers S, Bodis S. Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: a systematic review and meta-analysis along with therapeutic implications. Int J Radiat Oncol Biol Phys. 2017;99:573\u201389.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"520_CR37","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860\u20138.","journal-title":"J Clin Oncol"},{"key":"520_CR38","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","volume":"36","author":"KE Hoffman","year":"2018","unstructured":"Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018;36:2943\u20139.","journal-title":"J Clin Oncol"},{"key":"520_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, Boer HDe, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020;147:92\u20138.","journal-title":"Radiother Oncol"},{"key":"520_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1188\/16.ONF.199-218","volume":"43","author":"H Baker","year":"2016","unstructured":"Baker H, Wellman S, Lavender V. Functional quality-of-life outcomes reported by men treated for localized prostate cancer: a systematic literature review. Oncol Nurs Forum. 2016;43:199\u2013218.","journal-title":"Oncol Nurs Forum"},{"key":"520_CR41","first-page":"7599","volume":"22","author":"TK Lee","year":"2015","unstructured":"Lee TK, Breau RH, Mallick R, Eapen L. A systematic review of expanded prostate cancer index composite (EPIC) quality of life after surgery or radiation treatment. Can J Urol. 2015;22:7599\u2013606.","journal-title":"Can J Urol"},{"key":"520_CR42","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/pon.3776","volume":"24","author":"DRH Christie","year":"2015","unstructured":"Christie DRH, Sharpley CF, Bitsika V. Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer. Psychooncology. 2015;24:1002\u201311.","journal-title":"Psychooncology"},{"key":"520_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11764-015-0481-8","volume":"10","author":"S Bernard","year":"2016","unstructured":"Bernard S, Ouellet MP, Moffet H, Roy JS, Dumoulin C. Effects of radiation therapy on the structure and function of the pelvic floor muscles of patients with cancer in the pelvic area: a systematic review. J Cancer Survivorship. 2016;10:351\u201362.","journal-title":"J Cancer Survivorship"},{"issue":"Supplement 1","key":"520_CR44","first-page":"e1146","volume":"197","author":"T Gaither","year":"2017","unstructured":"Gaither T, Awad M, Osterberg EC, Murphy G, Allen I, Chang A, et al. Erectile dysfunction after prostatic radiotherapy: why measurement matters, a systematic review and meta-analysis. J Urol. 2017;197 4 Supplement 1:e1146.","journal-title":"J Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00520-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:16:12Z","timestamp":1700302572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00520-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00520-x","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The findings of the review will be submitted for peer-reviewed publications and presented at scientific meetings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}